Ask AI
ProCE Banner Series

From Evidence to Action: Expert Strategies for Individualizing CD38-Based Quadruplet Therapy in Transplant-Eligible NDMM

Join us in person or online for this interactive symposium in conjunction with the European Society for Blood and Marrow Transplantation (EBMT) 2026 annual meeting to hear from experts on the latest cutting-edge evidence and guidance needed to provide personalized frontline treatment with CD38-based quadruplet regimens.

Satellite Symposium of EBMT 2026

  AMA
Who Should Attend

This activity is intended for European bone marrow transplant specialists, hematologists, medical oncologists, and other healthcare professionals caring for patients with newly diagnosed multiple myeloma.

All Events

From Evidence to Action: Expert Strategies for Individualizing CD38-Based Quadruplet Therapy in Transplant-Eligible NDMM

Upcoming Events

March

23

2026

1:00 PM - 2:00 PM Central European Time (CET)

In-personVirtual

IFEMA Madrid, Puerta Norte Avda. del Partenón 5, 28042, Madrid, Spain

Topics

Multiple myeloma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence in the management of patients with transplant-eligible newly diagnosed multiple myeloma. 

Target Audience
This activity is intended for European bone marrow transplant specialists, hematologists, medical oncologists, and other healthcare professionals caring for patients with newly diagnosed multiple myeloma.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Develop individualized treatments leveraging anti-CD38 antibody–based quadruplet regimens for patients with newly diagnosed transplant-eligible MM based on current data, approvals, clinical data, expert recommendations, and patient/disease factors
  • Assess the clinical utility of MRD for guiding maintenance therapy and other treatment decisions in the induction setting for patients with transplant-eligible MM
  • Plan supportive care approaches to mitigate the risk of treatment-related adverse events in patients with newly diagnosed MM initiating treatment with anti-CD38 antibody–based quadruplet regimens
  • Appraise emerging data for novel methods of anti-CD38 antibody administration and their implications for reducing treatment burden among patients, caregivers, and HCPs
  • Implement strategies supporting equitable access to anti-CD38 antibody–based quadruplet regimens and supportive care in underserved patients with transplant-eligible MM

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191